Old Web
English
Sign In
Acemap
>
authorDetail
>
N. B. Amin
N. B. Amin
Pfizer
Endocrinology
Internal medicine
Medicine
Diabetes mellitus
Metformin
8
Papers
232
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF‐04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin—A Randomized, Crossover, Active‐Controlled Study
2016
Clinical pharmacology in drug development
William S. Denney
Douglas S Denham
Michael R. Riggs
N. B. Amin
Show All
Source
Cite
Save
Citations (9)
Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes
2015
Diabetes, Obesity and Metabolism
N. B. Amin
N. Aggarwal
Dénes Páll
György Paragh
William S. Denney
V. Le
M. Riggs
Roberto A. Calle
Show All
Source
Cite
Save
Citations (27)
Dose‐ranging efficacy and safety study of ertugliflozin, a sodium‐glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin
2015
Diabetes, Obesity and Metabolism
N. B. Amin
X. Wang
S. M. Jain
D. S. Lee
G. Nucci
J. M. Rusnak
Show All
Source
Cite
Save
Citations (49)
Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects.
2013
Drug Metabolism and Disposition
Zhuang Miao
Gianluca Nucci
N. B. Amin
Raman Sharma
Vincent Mascitti
Meera Tugnait
Alfin D. N. Vaz
Ernesto Callegari
Amit S. Kalgutkar
Show All
Source
Cite
Save
Citations (82)
1